HK1184686A1 - 用於治療乾眼症的地誇磷索和透明質酸或其鹽 - Google Patents

用於治療乾眼症的地誇磷索和透明質酸或其鹽

Info

Publication number
HK1184686A1
HK1184686A1 HK13112123.0A HK13112123A HK1184686A1 HK 1184686 A1 HK1184686 A1 HK 1184686A1 HK 13112123 A HK13112123 A HK 13112123A HK 1184686 A1 HK1184686 A1 HK 1184686A1
Authority
HK
Hong Kong
Prior art keywords
diquafosol
salts
treatment
hyaluronic acid
dry eye
Prior art date
Application number
HK13112123.0A
Other languages
English (en)
Inventor
優子 七條
敦義 堂田
敬 長野
雅胤 中村
明日香 阪元
Original Assignee
參天制藥株式會社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 參天制藥株式會社 filed Critical 參天制藥株式會社
Publication of HK1184686A1 publication Critical patent/HK1184686A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Non-Alcoholic Beverages (AREA)
HK13112123.0A 2010-09-10 2013-10-28 用於治療乾眼症的地誇磷索和透明質酸或其鹽 HK1184686A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010203198 2010-09-10
PCT/JP2011/070578 WO2012033189A1 (ja) 2010-09-10 2011-09-09 Ｐ２ｙ2受容体作動薬およびヒアルロン酸またはその塩を組み合わせたことを特徴とするドライアイ治療剤、ドライアイの治療方法、ならびにその使用

Publications (1)

Publication Number Publication Date
HK1184686A1 true HK1184686A1 (zh) 2014-01-30

Family

ID=45810785

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13112123.0A HK1184686A1 (zh) 2010-09-10 2013-10-28 用於治療乾眼症的地誇磷索和透明質酸或其鹽

Country Status (19)

Country Link
US (1) US9006208B2 (zh)
EP (1) EP2614838B1 (zh)
JP (1) JP5956735B2 (zh)
KR (2) KR101707269B1 (zh)
CN (2) CN103096929A (zh)
AU (2) AU2011299851A1 (zh)
BR (1) BR112013005438B1 (zh)
CA (1) CA2810481C (zh)
DK (1) DK2614838T3 (zh)
EA (1) EA026680B1 (zh)
ES (1) ES2569246T3 (zh)
HK (1) HK1184686A1 (zh)
MX (1) MX336944B (zh)
MY (1) MY170198A (zh)
NZ (1) NZ608202A (zh)
PL (1) PL2614838T3 (zh)
SG (1) SG188482A1 (zh)
TW (1) TWI519301B (zh)
WO (1) WO2012033189A1 (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140221306A1 (en) * 2010-12-28 2014-08-07 Santen Pharmaceutical Co. Ltd Ophthalmic solution comprising diquafosol, method for producing the same, and method for inhibiting formation of insoluble precipitate
TR201820073T4 (tr) 2012-03-26 2019-01-21 Santen Pharmaceutical Co Ltd Diquafosol içeren göz damlası.
EP3613423B1 (en) 2013-07-10 2022-10-26 Matrix Biology Institute Compositions of hyaluronan with high elasticity and uses thereof
US9289494B2 (en) 2013-11-20 2016-03-22 RestorTears, LLC Method of treating ocular disorders with compounds found in Harderian gland secretions
JP6267003B2 (ja) * 2014-02-27 2018-01-24 参天製薬株式会社 ジクアホソルまたはその塩およびレバミピドまたはその塩を組み合わせたことを特徴とする涙液分泌促進剤
CN113143948A (zh) * 2015-06-05 2021-07-23 参天制药株式会社 以向佩戴有软性隐形眼镜的干眼症患者的眼中滴入的方式使用为特征的干眼症治疗剂
JP2017052723A (ja) * 2015-09-10 2017-03-16 株式会社Ｌｔｔバイオファーマ ドライアイ改善剤
PL3352766T3 (pl) 2015-09-24 2021-08-02 Matrix Biology Institute Kompozycie z hialuronanem o dużej elastyczności i sposoby ich użycia
EP3871682A1 (en) * 2016-10-14 2021-09-01 i.com Medical GmbH Method for establishing, restoring, and preserving homeostasis of the ocular surface
KR20190071674A (ko) 2016-10-21 2019-06-24 라이온 가부시키가이샤 안과용 제제 및 안과용 약
CN107096016B (zh) * 2017-06-26 2021-04-06 蒋广伟 一种缓解视力疲劳的滴液
RU2652581C1 (ru) * 2017-07-03 2018-04-26 федеральное государственное бюджетное образовательное учреждение высшего образования "Приволжский исследовательский медицинский университет" Министерства здравоохранения Российской Федерации Способ лечения роговично-конъюнктивального ксероза
KR102108552B1 (ko) * 2018-05-15 2020-05-08 한국세라믹기술원 히알루론산 마이크로비드의 제조 방법 및 상기 히알루론산 마이크로비드의 용도
CN109260146A (zh) * 2018-10-12 2019-01-25 广州大光制药有限公司 地夸磷索钠眼用即用型凝胶滴眼液及制备方法
CN113518646B (zh) 2019-02-27 2023-12-12 参天制药株式会社 含有地夸磷索或其盐，乙烯基系高分子及纤维素系高分子的眼科用组合物
TW202122094A (zh) * 2019-08-27 2021-06-16 日商參天製藥股份有限公司 含有迪夸弗索(diquafosol)或其鹽、及聚乙烯吡咯烷酮之水性眼科用組合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01115902A (ja) 1987-10-30 1989-05-09 Showa Sangyo Co Ltd ヒアルロン酸の製造法
US5900407A (en) * 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
ES2264197T3 (es) 1997-02-06 2006-12-16 Inspire Pharmaceuticals, Inc. Dinucleotidos y sus usos.
US7223744B2 (en) 1997-02-10 2007-05-29 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof
KR20010013797A (ko) 1997-07-25 2001-02-26 인스파이어 파마슈티컬스 인코퍼레이티드 디(우리딘 5'-테트라포스페이트) 염 및 그의 제조방법과용도
JP2003160491A (ja) 2001-09-11 2003-06-03 Santen Pharmaceut Co Ltd ジウリジンリン酸含有点眼液

Also Published As

Publication number Publication date
EA201390364A1 (ru) 2013-08-30
MX336944B (es) 2016-02-03
TWI519301B (zh) 2016-02-01
MY170198A (en) 2019-07-09
DK2614838T3 (en) 2016-05-02
JP2012077080A (ja) 2012-04-19
AU2017200821A1 (en) 2017-03-02
CN103096929A (zh) 2013-05-08
KR101707269B1 (ko) 2017-02-15
US20130172287A1 (en) 2013-07-04
CA2810481C (en) 2018-06-19
BR112013005438B1 (pt) 2021-09-21
MX2013002677A (es) 2013-06-13
EA026680B1 (ru) 2017-05-31
TW201216971A (en) 2012-05-01
AU2011299851A1 (en) 2013-04-04
EP2614838A1 (en) 2013-07-17
US9006208B2 (en) 2015-04-14
SG188482A1 (en) 2013-04-30
ES2569246T3 (es) 2016-05-09
BR112013005438A2 (pt) 2016-05-17
PL2614838T3 (pl) 2016-10-31
EP2614838B1 (en) 2016-04-20
JP5956735B2 (ja) 2016-07-27
WO2012033189A1 (ja) 2012-03-15
KR20130109130A (ko) 2013-10-07
EP2614838A4 (en) 2014-02-26
KR20170018462A (ko) 2017-02-17
AU2017200821B2 (en) 2018-08-30
CA2810481A1 (en) 2012-03-15
NZ608202A (en) 2014-08-29
CN106729718A (zh) 2017-05-31

Similar Documents

Publication Publication Date Title
HK1184686A1 (zh) 用於治療乾眼症的地誇磷索和透明質酸或其鹽
IL261768B (en) Devices and methods for tissue treatment
EP2640461A4 (en) SYSTEMS AND METHOD FOR TREATING THE DRY EYE
HK1209788A1 (zh) 用於治療溶酶體貯積症的方法和組合物
EP2884944A4 (en) REINFORCED PLAZENTAGE WET CRANE PLANTS AND METHOD FOR THEIR PRODUCTION AND USE
AP3482A (en) Branched 3-phenylpropionic acid derivatives and the use thereof
HK1201042A1 (zh) 用於治療干眼病的組合物
PL2521562T3 (pl) Ev576 do zastosowania w leczeniu zakażeń wirusowych dróg oddechowych
IL225793A0 (en) Methods and preparations for curing insulin-related medical conditions
PT2810599T (pt) Sistema de estimulação elétrica para o tratamento da apneia do sono
EP2763667A4 (en) ORGANONITRO THIOETHERIC COMPOUNDS AND MEDICAL USES THEREOF
HK1210941A1 (zh) 經修飾的透明質酸衍生物及其用途
HUE044715T2 (hu) siRNS és felhasználása eljárásokban és kompozíciókban szembajok kezelésére és/vagy megelõzésére
EP2861244A4 (en) TREATMENT OF SLEEP APNEA
HK1196535A1 (zh) 鹽及醫藥用途
ZA201307058B (en) Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment
HK1216721A1 (zh) 治療肝臟疾病或病狀的用途和方法
HK1214771A1 (zh) 用於治療皮膚病的製劑
HK1185924A1 (zh) 用於醫療器械和裝置的功能納米結構殼聚糖塗層
PT2456445E (pt) Agente para o tratamento de condições da pele
ZA201005770B (en) The treatment of damaged skin
ZA201505093B (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the treatment of atherosclerosis
AU2012900286A0 (en) "Methods of treatment or prophylaxis"
GB0911581D0 (en) Compositions for use in the treatment of dry eye

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20220909